Cumberland Pharmaceuticals (NASDAQ:CPIX) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) from a buy rating to a hold rating in a research report report published on Tuesday, Zacks.com reports.

According to Zacks, “Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company’s lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients. “

Shares of CPIX opened at $5.63 on Tuesday. The firm has a 50-day moving average price of $5.93 and a 200 day moving average price of $5.94. The firm has a market capitalization of $86.23 million, a PE ratio of 32.65 and a beta of 0.15. The company has a quick ratio of 1.67, a current ratio of 2.07 and a debt-to-equity ratio of 0.36. Cumberland Pharmaceuticals has a 52-week low of $4.83 and a 52-week high of $7.00.



Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.22. The firm had revenue of $11.90 million during the quarter, compared to analyst estimates of $10.70 million. Cumberland Pharmaceuticals had a negative net margin of 9.87% and a positive return on equity of 4.98%. On average, equities analysts expect that Cumberland Pharmaceuticals will post 0.28 EPS for the current year.

In other news, Director Gordon R. Bernard sold 13,264 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $6.31, for a total transaction of $83,695.84. Following the completion of the transaction, the director now owns 86,319 shares in the company, valued at approximately $544,672.89. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gordon R. Bernard sold 7,471 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $5.77, for a total transaction of $43,107.67. Following the transaction, the director now owns 59,673 shares of the company’s stock, valued at approximately $344,313.21. The disclosure for this sale can be found here. In the last quarter, insiders purchased 9,011 shares of company stock valued at $57,333 and sold 55,111 shares valued at $337,807. Corporate insiders own 39.38% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its position in shares of Cumberland Pharmaceuticals by 13.0% during the 2nd quarter. Renaissance Technologies LLC now owns 441,577 shares of the specialty pharmaceutical company’s stock valued at $2,813,000 after purchasing an additional 50,800 shares in the last quarter. BlackRock Inc. boosted its position in shares of Cumberland Pharmaceuticals by 17.2% during the 2nd quarter. BlackRock Inc. now owns 332,543 shares of the specialty pharmaceutical company’s stock valued at $2,118,000 after purchasing an additional 48,753 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Cumberland Pharmaceuticals by 6.9% during the 2nd quarter. Acadian Asset Management LLC now owns 104,498 shares of the specialty pharmaceutical company’s stock valued at $665,000 after purchasing an additional 6,765 shares in the last quarter. Finally, Bailard Inc. bought a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter valued at about $92,000. Institutional investors own 31.81% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Featured Story: Marijuana Stocks

Get a free copy of the Zacks research report on Cumberland Pharmaceuticals (CPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.